AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
AbCellera (ABCL) has announced an upcoming poster presentation at the American Association for Cancer Research (AACR) 116th Annual Meeting in Chicago. The presentation will showcase preclinical in vivo data on the company's PSMA x CD3 T-cell engagers for prostate cancer treatment.
The poster presentation, titled 'PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer' (Abstract #6012), will be presented in the Therapeutic Antibodies session on Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDT at Section 35, Board 7 of the McCormick Place Convention Center.
AbCellera (ABCL) ha annunciato una prossima presentazione di poster alla 116a Riunione Annuale dell'American Association for Cancer Research (AACR) a Chicago. La presentazione mostrerà dati preclinici in vivo sui potenziatori delle cellule T PSMA x CD3 per il trattamento del cancro alla prostata.
La presentazione del poster, intitolata 'I potenziatori delle cellule T PSMA x CD3 mostrano efficacia preclinica per il trattamento del cancro alla prostata' (Abstract #6012), sarà presentata nella sessione Anticorpi Terapeutici martedì 29 aprile, dalle 14:00 alle 17:00 CDT presso la Sezione 35, Lavagna 7 del McCormick Place Convention Center.
AbCellera (ABCL) ha anunciado una próxima presentación de póster en la 116ª Reunión Anual de la American Association for Cancer Research (AACR) en Chicago. La presentación mostrará datos preclínicos in vivo sobre los activadores de células T PSMA x CD3 para el tratamiento del cáncer de próstata.
La presentación del póster, titulada 'Los activadores de células T PSMA x CD3 muestran eficacia preclínica para el tratamiento del cáncer de próstata' (Resumen #6012), se presentará en la sesión de Anticuerpos Terapéuticos el martes 29 de abril, de 2:00 p.m. a 5:00 p.m. CDT en la Sección 35, Tablero 7 del McCormick Place Convention Center.
AbCellera (ABCL)는 시카고에서 열리는 미국 암 연구 협회 (AACR) 제116회 연례 회의에서 포스터 발표를 예정하고 있다고 발표했습니다. 이 발표는 전립선암 치료를 위한 회사의 PSMA x CD3 T세포 결합제에 관한 전임상 in vivo 데이터를 보여줄 것입니다.
'PSMA x CD3 T세포 결합제가 전립선암 치료를 위한 전임상 효능을 보여준다'는 제목의 포스터 발표(초록 #6012)는 4월 29일 화요일, 오후 2시부터 5시까지 CDT에 McCormick Place Convention Center의 섹션 35, 보드 7에서 진행됩니다.
AbCellera (ABCL) a annoncé une prochaine présentation de poster lors de la 116e Réunion Annuelle de l'American Association for Cancer Research (AACR) à Chicago. La présentation mettra en avant des données précliniques in vivo sur les engageurs de cellules T PSMA x CD3 pour le traitement du cancer de la prostate.
La présentation du poster, intitulée 'Les engageurs de cellules T PSMA x CD3 montrent une efficacité préclinique pour le traitement du cancer de la prostate' (Résumé #6012), sera présentée lors de la session Anticorps Thérapeutiques le mardi 29 avril, de 14h00 à 17h00 CDT à la Section 35, Panneau 7 du McCormick Place Convention Center.
AbCellera (ABCL) hat eine bevorstehende Posterpräsentation auf der 116. Jahrestagung der American Association for Cancer Research (AACR) in Chicago angekündigt. Die Präsentation wird präklinische In-vivo-Daten zu den PSMA x CD3 T-Zell-Engagern zur Behandlung von Prostatakrebs vorstellen.
Die Posterpräsentation mit dem Titel 'PSMA x CD3 T-Zell-Engager zeigen präklinische Wirksamkeit zur Behandlung von Prostatakrebs' (Abstract #6012) wird am Dienstag, den 29. April, von 14:00 bis 17:00 Uhr CDT in der Sitzung Therapeutische Antikörper in Abschnitt 35, Board 7 des McCormick Place Convention Center stattfinden.
- None.
- None.
Details on AbCellera’s poster presentation at AACR are as follows:
Title: PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer
Abstract Number: 6012
Session: Therapeutic Antibodies, Including Engineered Antibodies 2
Date and Time: Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDT
Location: Section 35, Board 7
About AbCellera’s T-Cell Engager Platform
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, the development of T-cell engagers has been limited due to challenges with efficacy and safety. To address these challenges, AbCellera developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality and costimulatory building blocks to enhance efficacy for difficult-to-treat cancers.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325165386/en/
Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(604)724-1242
Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116
Source: AbCellera Biologics Inc.
FAQ
What will AbCellera (ABCL) present at AACR 2025?
When and where is AbCellera's (ABCL) AACR 2025 presentation scheduled?
What is the abstract number for AbCellera's (ABCL) AACR presentation?
What type of cancer treatment is AbCellera (ABCL) researching according to the AACR presentation?
